We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
+20.14%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$220M
AUM Growth
-$14.8M
Cap. Flow
-$35.3M
Cap. Flow %
-16%
Top 10 Hldgs %
95.12%
Holding
19
New
2
Increased
1
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$8.62M
2
INNL
Innocoll Holdings plc Ordinary Shares
INNL
+$6.16M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$837K

Top Sells

Rank Stock Value
1
SUPN icon
Supernus Pharmaceuticals
SUPN
+$27.8M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$13.2M
3
CEMP
Cempra, Inc.
CEMP
+$3.37M
4
ZGNX
Zogenix, Inc.
ZGNX
+$3.13M
5
HPTX
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
+$2.87M

Sector Composition

Rank Sector Weight
1 Healthcare 86.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SIEN
1
DELISTED
Sientra, Inc.
SIEN
$55.2M 25.03%
219,901
– –
TARA icon
2
Protara Therapeutics
TARA
$220M
$36M 16.36%
50,447
– –
PRTK
3
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$33.5M 15.21%
1,301,413
– –
AMRN
4
Amarin Corp
AMRN
$298M
$19.8M 8.99%
404,374
– –
EVAR
5
DELISTED
Lombard Medical, Inc.
EVAR
$15.1M 6.86%
3,473,452
– –
CEMP
6
DELISTED
Cempra, Inc.
CEMP
$14.7M 6.69%
428,935
-95,350
-18% -$3.37M
DRNA
7
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$13.2M 5.98%
945,757
-26,977
-3% -$495K
TBRA
8
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$10.2M 4.61%
+589,244
New +$8.62M
INNL
9
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$7.95M 3.61%
+555,555
New +$6.16M
ZGNX
10
DELISTED
Zogenix, Inc.
ZGNX
$3.92M 1.78%
36,488
-255,414
-87% -$3.13M
ANTH
11
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$3.77M 1.71%
54,749
– –
RGLS
12
DELISTED
Regulus Therapeutics
RGLS
$3.59M 1.63%
2,728
– –
CCXI
13
DELISTED
ChemoCentryx, Inc.
CCXI
$1.77M 0.8%
215,000
+105,300
+96% +$837K
ACHV icon
14
Achieve Life Sciences
ACHV
$659M
$1.41M 0.64%
274
– –
DCOY
15
Decoy Therapeutics
DCOY
$2.19M
– –
0
– –
ZLCS
16
DELISTED
ZALICUS INC COM NEW
ZLCS
$45K 0.02%
7,896
– –
SUPN icon
17
Supernus Pharmaceuticals
SUPN
$2.59B
– –
-2,303,462
Closed -$27.8M
PTLA
18
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-347,349
Closed -$13.2M
HPTX
19
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
– –
-62,500
Closed -$2.87M

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q2 2015 Portfolio in Review

As of Q2 2015, Abingworth held 19 positions worth $220M, down 6.3% from $235M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Abingworth withdrew a net $35.3M in Q2 2015, closing 3 positions and reducing 3 holdings. Its most notable exit was Supernus Pharmaceuticals, an estimated $27.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 77% a quarter earlier.

Against the trend, Abingworth opened a new position in Tobira Therapeutics, Inc. Common Stock worth $10.2M.

  • Abingworth's largest Q2 2015 buy was Tobira Therapeutics, Inc. Common Stock: 589,244 shares worth $10.2M.
  • Abingworth added most to ChemoCentryx, Inc. in Q2 2015, an estimated $837K increase.
  • Abingworth's biggest Q2 2015 reduction was Cempra, Inc., cutting an estimated $3.37M.
  • Abingworth fully exited Supernus Pharmaceuticals in Q2 2015, selling an estimated $27.8M.
  • Abingworth's ten largest holdings make up 95% of its $220M portfolio in Q2 2015.
  • Abingworth opened 2 new positions and closed 3 in Q2 2015.
  • Abingworth's portfolio value fell 6.3% quarter-over-quarter to $220M.

Based on Abingworth's 13F filing for Q2 2015, filed 14 Aug 2015.